Rare disease medication and medical insurance cover this western city

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'> New drugs for rare diseases have been approved by the country on the market, and the drug indications belong to the diseases listed in the National Rare Disease Catalog and the innovative drugs for rare diseases that meet the characteristics of breakthrough treatment drugs, and are covered by Chengdu Medical Insurance.

New drugs for rare diseases have been approved by the country on the market, and the drug indications belong to the diseases listed in the National Rare Disease Catalog and the innovative drugs for rare diseases that meet the characteristics of breakthrough treatment drugs, and are covered by Chengdu Medical Insurance.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Chengdu is the latest local government to introduce new medicines for rare diseases after Hangzhou in Zhejiang, Foshan in Guangdong, Hunan and other places.

Chengdu is the latest local government to introduce new medicines for rare diseases after Hangzhou in Zhejiang, Foshan in Guangdong, Hunan and other places.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>According to Chengdu’s "Notice on Issues Concerning the Guarantee of Drugs for Rare Diseases", the western metropolis of Chengdu has put forward new regulations for new drugs for rare diseases.
According to Chengdu’s "Notice on Issues Concerning the Guarantee of Drugs for Rare Diseases", the western metropolis of Chengdu has put forward new regulations for new drugs for rare diseases.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The notice first pointed out that “in order to promote the construction of a multi-level medical security system and resolve the catastrophic expenditure risk of rare diseases on the families of insured persons, it is based on the guidance of the Chengdu Municipal Finance Bureau on the establishment of a rare disease drug guarantee mechanism.
Opinions" (Chengyibaofa [2021] No.
1) document, the relevant issues regarding the establishment of a "controllable cost and shared responsibility" drug protection mechanism for rare diseases in our city (hereinafter referred to as drug protection) are hereby notified as follows.
"The notice first pointed out that “in order to promote the construction of a multi-level medical security system and resolve the catastrophic expenditure risk of rare diseases on the families of insured persons, it is based on the guidance of the Chengdu Municipal Finance Bureau on the establishment of a rare disease drug guarantee mechanism.
Opinions" (Chengyibaofa [2021] No.
1) document, the relevant issues regarding the establishment of a "controllable cost and shared responsibility" drug protection mechanism for rare diseases in our city (hereinafter referred to as drug protection) are hereby notified as follows.
"544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>In terms of the scope of protection, 1) For the first application for the protection of rare disease drugs, one of the following conditions shall be metIn terms of the scope of protection, 1) For the first application for the protection of rare disease drugs, one of the following conditions shall be met544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>One:One:

1. Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.
   
   
2. Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.
   
   

Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.

Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.
Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.

Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.

Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.
Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(2) Those who have already enjoyed the protection benefits of drugs for rare diseases, the re-application should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits.
(2) Those who have already enjoyed the protection benefits of drugs for rare diseases, the re-application should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>New drugs covered include:New drugs covered include:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(1) The drug indications are diseases listed in the National Rare Disease Catalog ;(1) The drug indications are diseases listed in the National Rare Disease Catalog ;544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(2) The drug is a rare disease innovative drug that meets the characteristics of a breakthrough drug;(2) The drug is a rare disease innovative drug that meets the characteristics of a breakthrough drug;544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(3) Under the conditions of a medical insurance payment of 400,000 per year and a personal burden of 60,000 per year, patients can obtain continuous and standardized medication.
(3) Under the conditions of a medical insurance payment of 400,000 per year and a personal burden of 60,000 per year, patients can obtain continuous and standardized medication.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Guarantee standard:Guarantee standard:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The guarantee funds shall be calculated and reimbursed in stages within a treatment year for the costs of medicines used by patients in compliance with the provisions of this notice.
The annual drug cost limit is 460,000 yuan, of which the medical insurance payment limit is 400,000 yuan and the personal burden limit is 60,000 yuan .
The reimbursement rate for medicines within 200,000 yuan (including 200,000 yuan) in a treatment year is 70% , and the medicine expenses in the range of 200,000 yuan to 460,000 yuan (including 460,000 yuan) shall be settled by the guarantee funds according to the facts.
The guarantee funds shall be calculated and reimbursed in stages within a treatment year for the costs of medicines used by patients in compliance with the provisions of this notice.
The annual drug cost limit is 460,000 yuan, of which the medical insurance payment limit is 400,000 yuan and the personal burden limit is 60,000 yuan .
The reimbursement rate for medicines within 200,000 yuan (including 200,000 yuan) in a treatment year is 70% , and the medicine expenses in the range of 200,000 yuan to 460,000 yuan (including 460,000 yuan) shall be settled by the guarantee funds according to the facts.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The details are as follows:
The details are as follows:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Sichuan Tianfu New District Community Governance and Social Affairs Bureau, Sichuan Tianfu New District Finance and Finance Bureau, Chengdu Eastern New Area Public Service Bureau, Chengdu Eastern New Area Finance and Finance Bureau, Chengdu High-tech Zone Social Governance Security Bureau, Chengdu High-tech Zone Finance and Finance Bureau, Chengdu High-tech Zone Education Culture and Health Bureau, District (City) and County Medical Insurance Bureau, Finance Bureau, Health and Health Bureau, Municipal Medical Insurance Affairs Center, and Municipal Medical Insurance Information Center:Sichuan Tianfu New District Community Governance and Social Affairs Bureau, Sichuan Tianfu New District Finance and Finance Bureau, Chengdu Eastern New Area Public Service Bureau, Chengdu Eastern New Area Finance and Finance Bureau, Chengdu High-tech Zone Social Governance Security Bureau, Chengdu High-tech Zone Finance and Finance Bureau, Chengdu High-tech Zone Education Culture and Health Bureau, District (City) and County Medical Insurance Bureau, Finance Bureau, Health and Health Bureau, Municipal Medical Insurance Affairs Center, and Municipal Medical Insurance Information Center:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>In order to promote the construction of a multi-level medical security system and resolve the catastrophic expenditure risk of rare diseases on the families of insured persons, according to the "Guiding Opinions of Chengdu Municipal Finance Bureau on the Establishment of Rare Disease Drug Guarantee Mechanism" (Cheng Medical Insurance issued [2021] No.
1) The spirit of the document is hereby notified as follows regarding the establishment of a "controllable cost and shared responsibility" drug protection mechanism for rare diseases in our city (hereinafter referred to as drug protection).
In order to promote the construction of a multi-level medical security system and resolve the catastrophic expenditure risk of rare diseases on the families of insured persons, according to the "Guiding Opinions of Chengdu Municipal Finance Bureau on the Establishment of Rare Disease Drug Guarantee Mechanism" (Cheng Medical Insurance issued [2021] No.
1) The spirit of the document is hereby notified as follows regarding the establishment of a "controllable cost and shared responsibility" drug protection mechanism for rare diseases in our city (hereinafter referred to as drug protection).
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>1.
The guarantee object1.
The guarantee object544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(1) For the first application for the protection of drugs for rare diseases, one of the following conditions shall be met:(1) For the first application for the protection of drugs for rare diseases, one of the following conditions shall be met:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>1.
Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu Mutual Medical Mutual Assistance Insurance Benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.
1.
Patients who are 5 years old (including 5 years old) and above should be in the benefit period of Chengdu Mutual Medical Mutual Assistance Insurance Benefits, and the cumulative number of months of participating in the insurance payment has reached 60 months.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>2.
Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.
2.
Patients under the age of 5 should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits, and either of their parents has participated in the critical illness mutual medical supplementary insurance, and the cumulative number of months of participating in the insurance payment has reached 60 months.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(2) Those who have already enjoyed the protection benefits of drugs for rare diseases, the re-application should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits.
(2) Those who have already enjoyed the protection benefits of drugs for rare diseases, the re-application should be in the benefit period of Chengdu's critical illness medical mutual assistance supplementary insurance benefits.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Second, the scope of protectionSecond, the scope of protection544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Rare disease drugs that have been approved for marketing in China and meet the following requirements can apply for inclusion in the coverage of this medication:Rare disease drugs that have been approved for marketing in China and meet the following requirements can apply for inclusion in the coverage of this medication:544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(1) The drug indications are diseases listed in the National Rare Disease Catalog;(1) The drug indications are diseases listed in the National Rare Disease Catalog;544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(2) The drug is a rare disease innovative drug that meets the characteristics of a breakthrough drug;(2) The drug is a rare disease innovative drug that meets the characteristics of a breakthrough drug;544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(3) Under the conditions of a medical insurance payment of 400,000 per year and a personal burden of 60,000 per year, patients can obtain continuous and standardized medication.
(3) Under the conditions of a medical insurance payment of 400,000 per year and a personal burden of 60,000 per year, patients can obtain continuous and standardized medication.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>If the medicines that meet the above conditions are included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog" under the second paragraph of their indications, the corresponding drug indications will not be included in or withdrawn from this medication guarantee range.
If the medicines that meet the above conditions are included in the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog" under the second paragraph of their indications, the corresponding drug indications will not be included in or withdrawn from this medication guarantee range.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Newly approved drugs for rare diseases in China that meet the above conditions and are not higher than the annual drug costs of drugs with the same indication that have been included in the coverage can apply to be included in the coverage of drug coverage.
Newly approved drugs for rare diseases in China that meet the above conditions and are not higher than the annual drug costs of drugs with the same indication that have been included in the coverage can apply to be included in the coverage of drug coverage.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>3.
Guaranteed funds3.
Guaranteed funds544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Rare disease drug protection funds (hereinafter referred to as "guarantee funds") are mainly derived from the supplementary insurance funds for major illness medical mutual assistance in Chengdu, with separate account accounting and clearing of the balance.
Rare disease drug protection funds (hereinafter referred to as "guarantee funds") are mainly derived from the supplementary insurance funds for major illness medical mutual assistance in Chengdu, with separate account accounting and clearing of the balance.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(1) Source of funds.
Raise funds for rare disease protection based on 2% of the total funding of the critical illness medical mutual assistance supplementary insurance in the previous year.
The Municipal Medical Insurance Bureau, in conjunction with the Municipal Finance Bureau, will adjust the fund-raising ratio according to the operation of the guarantee funds.
(1) Source of funds.
Raise funds for rare disease protection based on 2% of the total funding of the critical illness medical mutual assistance supplementary insurance in the previous year.
The Municipal Medical Insurance Bureau, in conjunction with the Municipal Finance Bureau, will adjust the fund-raising ratio according to the operation of the guarantee funds.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(2) Overexpenditure sharing.
When the annual guarantee fund exceeds the estimated amount of guarantee fund used in the year, the supplementary insurance fund for critical illness medical mutual assistance and the drug manufacturer (or supplier) shall be jointly shared.
The specific sharing method shall be separately formulated by the municipal medical insurance agency.
(2) Overexpenditure sharing.
When the annual guarantee fund exceeds the estimated amount of guarantee fund used in the year, the supplementary insurance fund for critical illness medical mutual assistance and the drug manufacturer (or supplier) shall be jointly shared.
The specific sharing method shall be separately formulated by the municipal medical insurance agency.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>(3) The balance is returned.
The current balance of the guarantee funds shall be cleared to zero.
(3) The balance is returned.
The current balance of the guarantee funds shall be cleared to zero.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Four, guarantee standardsFour, guarantee standards544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The guarantee funds shall be calculated and reimbursed in stages within a treatment year for the costs of medicines used by patients in compliance with the provisions of this notice.
The annual drug cost limit is 460,000 yuan, of which the medical insurance payment limit is 400,000 yuan and the personal burden limit is 60,000 yuan.
The reimbursement ratio for medicines within 200,000 yuan (including 200,000 yuan) in a treatment year is 70%, and the medicine expenses in the range of 200,000 yuan to 460,000 yuan (including 460,000 yuan) shall be settled by the guarantee funds according to the facts.
The guarantee funds shall be calculated and reimbursed in stages within a treatment year for the costs of medicines used by patients in compliance with the provisions of this notice.
The annual drug cost limit is 460,000 yuan, of which the medical insurance payment limit is 400,000 yuan and the personal burden limit is 60,000 yuan.
The reimbursement ratio for medicines within 200,000 yuan (including 200,000 yuan) in a treatment year is 70%, and the medicine expenses in the range of 200,000 yuan to 460,000 yuan (including 460,000 yuan) shall be settled by the guarantee funds according to the facts.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Five, management servicesFive, management services544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Rare disease management services mainly include the scope of protection of rare disease drugs, certification standards, institutional management, medical treatment management, settlement management, and agreement management.
The scope of drugs is determined by enterprise declaration and expert review.
Experts formulate the "Chengdu City Rare Disease Drug Coverage and Drug Recognition Standards" based on rare disease diagnosis and treatment guidelines, clinical drug requirements, drug instructions, drug guidelines, and expert consensus, and establish a dynamic adjustment mechanism.
Medical institutions with the ability to diagnose and treat rare diseases are responsible for the identification and diagnosis and treatment of rare diseases.
Special drug pharmacies selected by rare disease drug manufacturers (suppliers) as designated distribution agencies for rare disease drugs.
Patients with rare diseases should seek medical treatment at designated rare disease medical institutions, and purchase and settle drugs at designated pharmacies for rare disease drugs.
The Municipal Medical Insurance Affairs Center shall sign an agreement with the rare disease drug manufacturer (or supplier), and the agreement shall be signed for a period of 2 years.
Pharmaceutical manufacturers (suppliers) shall not voluntarily propose to suspend or terminate the agreement (except for the withdrawal of drugs covered by rare diseases from the Chinese market).
Based on this, the Municipal Medical Security Affairs Center formulates relevant management measures and organizes their implementation.
Rare disease management services mainly include the scope of protection of rare disease drugs, certification standards, institutional management, medical treatment management, settlement management, and agreement management.
The scope of drugs is determined by enterprise declaration and expert review.
Experts formulate the "Chengdu City Rare Disease Drug Coverage and Drug Recognition Standards" based on rare disease diagnosis and treatment guidelines, clinical drug requirements, drug instructions, drug guidelines, and expert consensus, and establish a dynamic adjustment mechanism.
Medical institutions with the ability to diagnose and treat rare diseases are responsible for the identification and diagnosis and treatment of rare diseases.
Special drug pharmacies selected by rare disease drug manufacturers (suppliers) as designated distribution agencies for rare disease drugs.
Patients with rare diseases should seek medical treatment at designated rare disease medical institutions, and purchase and settle drugs at designated pharmacies for rare disease drugs.
The Municipal Medical Insurance Affairs Center shall sign an agreement with the rare disease drug manufacturer (or supplier), and the agreement shall be signed for a period of 2 years.
Pharmaceutical manufacturers (suppliers) shall not voluntarily propose to suspend or terminate the agreement (except for the withdrawal of drugs covered by rare diseases from the Chinese market).
Based on this, the Municipal Medical Security Affairs Center formulates relevant management measures and organizes their implementation.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Six, implementation timeSix, implementation time544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>This notice will be implemented on January 1, 2021, and will be valid for 5 years.
This notice will be implemented on January 1, 2021, and will be valid for 5 years.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>Seven, otherSeven, other544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>The municipal medical insurance agency may formulate handling and management measures based on this notice.
Before the implementation of this notice, the medical insurance policies related to rare diseases will continue to be effective; after the medicines that have a donation program in China are included in the city’s rare disease medicine guarantee, the original donation of medicines shall not be reduced.
The municipal medical insurance agency may formulate handling and management measures based on this notice.
Before the implementation of this notice, the medical insurance policies related to rare diseases will continue to be effective; after the medicines that have a donation program in China are included in the city’s rare disease medicine guarantee, the original donation of medicines shall not be reduced.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;text-indent:2em;box-sizing:border-box ;overflow-wrap:break-word ;'>544px;white-space:normal;background-color:#FFFFFF;text-indent:2em;text-align:right;box-sizing:border-box ;overflow-wrap:break-word ;'>Chengdu Medical Security BureauChengdu Medical Security Bureau544px;white-space:normal;background-color:#FFFFFF;text-indent:2em;text-align:right;box-sizing:border-box ;overflow-wrap:break-word ;'>Chengdu Finance BureauChengdu Finance Bureau544px;white-space:normal;background-color:#FFFFFF;text-indent:2em;text-align:right;box-sizing:border-box ;overflow-wrap:break-word ;'>Chengdu Municipal Health CommissionChengdu Municipal Health Commission544px;white-space:normal;background-color:#FFFFFF;text-indent:2em;text-align:right;box-sizing:border-box ;overflow-wrap:break-word ;'>January 18, 2021January 18, 2021